Standard BioTools Inc

Insider RSU purchases by Standard BioTools’ board confirm strong long‑term confidence in its breakthrough mass‑cytometry and microfluidic diagnostics, despite some executive sales.

Insider buys at Standard BioTools reveal confidence in its mass‑cytometry tech, but the unprofitable biotech still faces cash‑burn risks and regulatory hurdles. Read on to gauge next‑step growth and investor sentiment.